100599-91-5

Basic information

• Product Name: 4-METHYLTHIAZOL-2-YLGUANIDINE HYDROCHLORIDE
• Synonyms: 4-METHYLTHIAZOL-2-YLGUANIDINE HYDROCHLORIDE 97%;1-(4-Methyl-1,3-thiazol-2-yl)guanidine hydrochloride;4-METHYLTHIAZOL-2-YLGUANIDINE HYDROCHLORIDE;N-(4-METHYL-1,3-THIAZOL-2-YL)GUANIDINE HYDROCHLORIDE;4-Methylthiazol-2-ylguanidineHCl
• CAS NO: 100599-91-5
• Molecular Formula: C5H9ClN4S
• Molecular Weight: 192.67
• Product Categories: Thiazoles, Isothiazoles & Benzothiazoles
• Mol File: 100599-91-5.mol
• Article Data: 3

Chemical Properties

• Melting Point: 198-200°C
• Boiling Point: 346.7°Cat760mmHg
• Flash Point: 163.5°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 5.65E-05mmHg at 25°C
• Storage Temp.: Refrigerator
• Solubility: Water
• CAS DataBase Reference: 4-METHYLTHIAZOL-2-YLGUANIDINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHYLTHIAZOL-2-YLGUANIDINE HYDROCHLORIDE(100599-91-5)
• EPA Substance Registry System: 4-METHYLTHIAZOL-2-YLGUANIDINE HYDROCHLORIDE(100599-91-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S36:Wear suitable prot
• WGK Germany: 3
• Hazardous Substances Data: 100599-91-5(Hazardous Substances Data)

Usage

Description

4-METHYLTHIAZOL-2-YLGUANIDINE HYDROCHLORIDE, also known as N-(4-METHYL-2-THIAZOLYL)-GUANIDINE HYDROCHLORIDE, is a chemical compound that serves as a test compound in various scientific studies. It is particularly useful in research involving the permeability of substances through the blood-brain barrier, which is a critical aspect of drug development and understanding the delivery of therapeutic agents to the brain.

Uses

Used in Pharmaceutical Research:
4-METHYLTHIAZOL-2-YLGUANIDINE HYDROCHLORIDE is used as a test compound for studying the permeability of substances through the blood-brain barrier. This application is crucial in the development of drugs that target the central nervous system, as it helps researchers understand how well a compound can cross the barrier and reach the brain.
In this context, the compound serves as a benchmark for evaluating the effectiveness of other potential therapeutic agents in crossing the blood-brain barrier. This information is vital for the design and optimization of new drugs that aim to treat neurological disorders and conditions.
Additionally, the compound may also be used in other research areas, such as the study of drug delivery systems, to improve the understanding of how different factors can influence the transport of substances across biological barriers.

InChI:InChI=1/C5H8N4S.ClH/c1-3-2-10-5(8-3)9-4(6)7;/h2H,1H3,(H4,6,7,8,9);1H

Upstream product

• 2114-02-5 amidinothiocarbamide 
• 78-95-5 chloroacetone 
• 2114-02-5 guanylthiourea 

Relevant articles and documents

Arylbiamidines: Synthesis and structural studies en route to anticancer applications

Biamidines are a unique and poorly studied class of nitrogenous compounds prone to tautomerization and H-bonding. Four series of heteroaryl diarylbiamidines were synthesized and the antimelanoma activity and physicochemical properties of the resulting 37 new compounds were evaluated. The dimethylthiazolyl 3-bromophenyl biamidine derivative B6 inhibits the growth of six different melanoma cell lines, having higher activity than the positive control drug, the B-RAF inhibitor PLX4032. This study introduces diarylbiamidines as promising frameworks for drug discovery.

Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists

A rational approach to the design of centrally acting agents is presented, based initially upon a comparison of the physicochemical properties of three typical histamine H2 receptor antagonists which do not readily cross the blood-brain barrier with those of the three brain-penetrating drugs clonidine (6), mepyramine (7), and imipramine (8). A good correlation was found between the logarithms of the equilibrium brain/blood concentration ratios in the rat and the partition parameter, Δ log P, defined as log P (1-octanol/water) - log P (cyclohexane/water), which suggests that brain penetration might be improved by reducing overall hydrogen-bonding ability. This model has been employed as a guide in the design of novel brain-penetrating H2 antagonists by the systematic structural modification of representatives of different structural types of H2 antagonists. Although marked increases in brain penetration amongst congeners of cimetidine (1), ranitidine (9), and tiotidine (10) were achieved, no compound was found with an acceptable combination of H2 antagonist activity (-log K(B) in the guinea pig atrium > 7.0) and brain penetration (steady-state brain/blood concentration ratio > 1.0). Conversely, structural modification of N-[[(piperidinylmethyl)phenoxy]propyl]acetamide (30) led to several potent, novel compounds which readily cross the blood-brain barrier. One of these, zolantidine (SK&F 95282, 41), whose -log K(B) is 7.46 and steady-state brain/blood ratio is 1.4, has been identified for use in studying histaminergic H2 receptor mechanisms in brain. Comparison of Δ log P values with the logarithms of the brain/blood ratios for 20 structurally diverse compounds for which data became available confirms a highly significant correlation and supports the general validity of this model.